Safety and efficacy of plasma transfusion from exercise-trained donors in patients with early Alzheimer’s disease: protocol for the ExPlas study

Author:

Tari Atefe RORCID,Berg Helene Haugen,Videm Vibeke,Bråthen Geir,White Linda R,Røsbjørgen Ragnhild Nyhus,Scheffler Katja,Dalen Havard,Holte Espen,Haberg Asta K,Selbaek GeirORCID,Lydersen Stian,Duezel Emrah,Bergh Sverre,Logan-Halvorsrud Kjell Rune,Sando Sigrid Botne,Wisløff UlrikORCID

Abstract

IntroductionGiven that exercise training reduces the risk of developing Alzheimer’s disease (AD), induces changes in the blood composition and has widespread systemic benefits, it is reasonable to hypothesise that exercised plasma (ExPlas) may have rejuvenative properties. The main objective is to test safety and tolerability of transfusing ExPlas from young, healthy, fit adults to patients with mild cognitive impairment (MCI) or early AD. The study is a pilot for a future efficacy study. The key secondary objectives are examining the effect of plasma transfusions on cognitive function, fitness level, vascular risk profile, assessment of cerebral blood flow and hippocampal volume, quality of life, functional connectivity assessed by resting state functional MRI and biomarkers in blood and cerebrospinal fluid.Methods and analysisExPlas is a double-blinded, randomised controlled clinical single-centre trial. Patients up to 75 years of age with diagnosis early symptomatic phase AD will be recruited from two Norwegian hospitals. ExPlas is plasma drawn by plasmapheresis once a month for 4 months, from a total of 30 fit male donors (aged 18–40, BMI≤27 kg/m2 and maximal oxygen uptake>55 mL/kg/min). All units will be virus inactivated by the Intercept method in accordance with procedures at St. Olavs University Hospital. Comparison with isotonic saline allows differentiation from a non-blood product. The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions divided over three 4-week periods during study year-1. It is also planned to conduct follow-up examinations 2 and 5 years after baselineEthics and disseminationWritten informed consent will be obtained from all participants and participation is voluntary. All participants have a next of kin who will follow them throughout the study to represent the patient’s interest. The study is approved by the Regional Committee for Medical and Health Research Ethics (REK 2018/702) and the Norwegian Medicines Agency (EudraCT No. 2018-000148-24). The study will be published in an open access journal and results will be presented at numerous national and international meetings as well as on social media platforms.Trial registration numberEudraCT No. 2018-000148-24. ClinicalTrials.gov, NCT05068830

Funder

Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology

Helse Midt-Norge

The National Associsiation for Public Health Norway

St. Olavs University Hosptial

Norges Forskningsråd

K.G. Jebsen Foundation for Medical Research, Norway

Publisher

BMJ

Subject

General Medicine

Reference68 articles.

1. World Health Organization . Aging and life course, 2015. Available: http://www.who.int/ageing/en/

2. alz.org. Alzheimer’s Disease Facts and Figures [Report], 2018 [updated 2018. 5,8]. Available from:. Available: http://www.alz.org

3. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions

4. d H . Demensplan, 2025.

5. Current and future prevalence estimates of mild cognitive impairment, dementia, and its subtypes in a population-based sample of people 70 years and older in Norway: the HUNT study;GjØra;J Alzheimers Dis,2021

Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3